CD19 and myeloid sarcoma: Furthermore, an Italian report on 83 RRMS patients whose infusion was scheduled between March and December 2020 reported the experience of 56 patients whose treatments were delayed based on MS severity and SARS-CoV-2 infection risk profile with strict CD19 + B-cell repopulation rate monitoring [24].